Mark Leuchtenberger joined Targanta from Therion Biologics Corporation, a privately held cancer vaccine company, where he served as President and Chief Executive Officer from 2002 to 2006. Under his leadership Therion filed its first IND, progressed through Phase 3 trials, completed the buildup of its commercial manufacturing capabilities, and raised over $120 million in three rounds of private financings.
In late June 2006, Therion announced disappointing results from a 255-patient Phase 3 trial of its lead cancer vaccine for advanced pancreatic cancer. The trial did not meet its primary efficacy endpoint of improving overall survival compared with palliative chemotherapy or best supportive care, and the company no longer plans to file a Biologics License Application (BLA) with the FDA. Therion also announced that its investors have identified an investment bank to manage the sale of the company. The sales process will commence immediately.
Prior to joining Therion, Mark served as Vice President, International at Biogen, where he served as Vice President, International from 1999-2002. In this capacity, he led all commercial operations outside of North America. He joined Biogen in 1990 as Product Manager, and earlier served as Program Executive for Biogen's commercial products Amevive� and Avonex�. In the latter role, Mr. Leuchtenberger was responsible for managing the late-stage development, registration, marketing and North American launch of Avonex�. During his tenure at Biogen, he held several senior positions, including Vice President of Sales, Marketing and Business Development where he oversaw Biogen's global market, licensing and strategic partnership activities. Prior to Biogen, he worked as a Senior Consultant at Bain and Company and specialized in healthcare products and services.
Mr. Leuchtenberger received an M.B.A. from the Yale School of Management and a B.A. from Wake Forest University. Mr. Leuchtenberger also serves on boards for the Massachusetts Biotechnology Council, Beth Israel Deaconess Medical Center and Wake Forest University.